Anaclim

Anaclim is a Contract Research Organization that recruits members of ethnic minorities into clinical research trials. It is the first minority recruitment-focused CRO in the United States.

Background
Through the years, ethnic minorities have been consistently under-represented in clinical research conducted by academic institutions, government or private pharmaceutical and biotechnology companies. Even though ethnic minorities today constitute a third of the population of the United States, according to data from the Food and Drug Administration (FDA), only about 15% of all the patients included in clinical trials aimed at obtaining registration approval of new drugs and treatments belong to a minority group. This is truth even for diseases that affect with a disproportionately higher incidence patients who are members of ethnic minority groups. Such is the case for clinical trials studying diabetes, hypertension, stroke, acute coronary syndrome, AIDS, prostate cancer and many other diseases that are more prevalent in ethnic minotity members.

Anaclim, LLC was created with the intention of addressing the issue of under-representation of ethnic minorities in clinical trials. Anaclim, LLC was constituted on March 8, 2005. From March through November, 2005 all regulatory and clinical development processes and procedures, information technology systems and quality checks were developed and put in place at Anaclim and after an extensive audit of its operations Anaclim opened its doors on December 1, 2005.

Recruitment
Anaclim specializes in the recruitment of ethnic minority members into clinical trials. These services can be provided in one of two forms, according to the needs of the sponsors of these trials. First, Anaclim can join forces with the sponsor or with another entity hired by the sponsor (i.e. another CRO) to supply the "ethnic minority part" of a population of patients wishing to be studied by the sponsor. Second, Anaclim can be asked by the sponsor to implement a clinical trial in its entirety enrolling a "representative patient sample" of the disease being studied. In this case Anaclim will implement the entire clinical trial.